Skip to main content Accessibility help
×
Home
  • Cited by 2
  • Print publication year: 2012
  • Online publication date: November 2012

6 - Vaccine research and development

Summary

Thirty years have passed since the recognition of the infectious disease now named acquired immune deficiency syndrome (AIDS). In that relatively short time AIDS has killed over 30 million individuals, and an additional 33.3 million people are now living with the infection. Africa shoulders the burden of the epidemic: UNAIDS estimates that in 2009 1.3 million people died from AIDS in Africa, 22.5 million were living with HIV, and a further 1.5 million acquired the infection during the year. Even though prevention and treatment programs are expanding, the epidemic is holding its ground. Only two out of every five people requiring anti-retroviral therapy currently have access to treatment – and this number is threatened by financial pressures of the global recession. Though universal access to treatment is a morally compelling goal, the high costs associated with treatment argue for a strategy that emphasizes prevention.

An AIDS vaccine is the ultimate goal of prevention – vaccination would provide a manageable and affordable way to confer protection against HIV infection. When fully developed and licensed, an AIDS vaccine could have a powerful and immediate impact; the International AIDS Vaccine Initiative (IAVI) estimates that an AIDS vaccine of 50 percent efficacy given to just 30 percent of the population could reduce the number of new infections in the developing world by 24 percent in fifteen years (IAVI 2009a). Yet AIDS vaccine development is proving to be enormously expensive. Is the perhaps $15–20 billion of additional resources that it may cost the world to develop an AIDS vaccine worth it?

References
Adams, C. PBrantner, V. ( 2010 Spending on new drug developmentHealth Economics 19 130
aids2031 Costs and Financing Working Group 2010 Costs and Choices: Financing the Long-Term Fight against AIDSWashington, DC:Results for Development Institute
aids2031 Costs and Financing Working Group 2010 The Long-Term Costs of HIV/AIDS in South AfricaWashington, DCResults for Development Institute
ALPHA Network 2011 www.lshtm.ac.uk/eph/psd/alpha/phase1/
Aral, S. O.Holmes, K. K. 2008 The epidemiology of STIs and their social and behavioral determinants: industrialized and developing countriesHolmes, K. K.Sparling, P.Stamm, W.Piot, P.Wasserheit, J.Corey, L.Cohen, M.Sexually Transmitted Diseases, 4th ednNew York:McGraw-Hill
Auvert, B.Taljaard, D.Lagarde, E.Sobngwi- Tambekou, J.Sitta, R.Puren, A. 2005 Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 TrialPLoS Medicine 2 1112
Bailey, R. C.Moses, S.Parker, C. B.Agot, K.Maclean, I.Krieger, J. N.Williams, C. F. M.Campbell, R. T.Ndinya-Achola, J. O. 2007 Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trialThe Lancet 369 643
Bertozzi, S.Guitierrez, J. P.Opuni, M.Bollinger, L.McGreevey, W.Stover, J. 2002 Resource Requirements to Fight HIV/AIDS in Latin America and the CaribbeanWashington, DC:Inter-American Development Bank
Bishai, D.Pariyo, G.Ainsworth, M.Hill, K. 2004 Determinants of personal demand for an AIDS vaccine in Uganda: contingent valuation surveyBulletin of the World Health Organization 82 652
Bloom, D. E.Canning, D.Jamison, D. T. 2004 Health, wealth, and welfareFinance and Development 40 10
Foster, G.Williamson, J. 2000 A review of current literature on the impact of HIV/AIDS on children in sub-Saharan AfricaAIDS 14 S275
Haacker, M. 2004 HIV/AIDS: The Impact on the Social Fabric and the Economy, in The Macroeconomics of HIV/AIDSGeneva:International Monetary Fund
Hammitt, J. K.Robinson, L.A. 2011 The income elasticity of the value per statistical life: transferring estimates between high and low income populationsJournal of Benefit-Cost Analysis 2 www.bepress.com/jbca/vol2/iss1/1/
Health Economics Research Group 2008 Medical Research: What's It Worth? Estimating the Economic Benefits from Medical Research in the UKLondon:UK Evaluation Forum
Hecht, R.Stover, J.Bollinger, L.Muhib, F.Case, KDe Ferranti, D. 2010 Financing of HIV/AIDS programme scale-up in low-income and middle-income countries 2009–2031The Lancet 376 1254
International AIDS Vaccine Initiative 2007 www.bcg.com/documents/file27442.pdf
International AIDS Vaccine Initiative 2009 www.iavi.org/Lists/IAVIPublications/attachments/2c678572-e031-4fc2-b4120794e04c9409/IAVI_Policy_Notes_Estimating_the_Potential_Impact_of_an_AIDS_Vaccine_in_Developing_Countries_2010_ENG.pdf
International AIDS Vaccine Initiative 2009 www.iavi.org/Lists/IAVIPublications/attachments/454d7f8e-f58a-4bf0-969436447fa52211/IAVI_Uganda_Estimating_the_Potential_Impact_of_an_AIDS_Vaccine_2009_ENG.pdf
International AIDS Vaccine Initiative 2010 www.iavi.org/Lists/IAVIPublications/attachments/59b6940e-e617-4287-b225a22611ede716/IAVI_Brazil_Estimating_the_Potential_Impact_of_an_AIDS_Vaccine_2010_ENG.pdf
International AIDS Vaccine Initiative 2010 www.iavi.org/Lists/IAVIPublications/attachments/3f762fb5-38f1-4e84-b1ea61eacc257417/IAVI_Kenya_Estimating_the_Potential_Impact_of_an_AIDS_Vaccine_2009_ENG.pdf
International AIDS Vaccine Initiative 2010 www.iavi.org/about-IAVI/Documents/IAVI_APR_2009.pdf
International AIDS Vaccine Initiative 2011 www.iavi.org/Lists/IAVIPublications/attachments/e7c3fa54-ed10-4dd4-b22b-0294202c8807/IAVI_Annual_Report_2010_ENG.pdf
Jamison, D. T.Jha, P.Bloom, D. E. 2008 Disease controlLomborg, B.Global Crises, Global Solutions: Costs and BenefitsCambridge University Press3
Jamison, D. T.Sachs, J. D.Wang, J. 2001 The effect of the AIDS epidemic on economic welfare in sub-Saharan AfricaCMH Working Paper Series No 13Geneva:World Health Organization
Karim, A. Q. 2010 Effectiveness and safety of Tenofovir gel, an anti-retroviral microbicide, for the prevention of HIV infection in womenScience 329 1168
Leelahavarong, P. 2011 Is a HIV vaccine a viable option and at what price? An economic evaluation of adding HIV vaccination into existing prevention programs in ThailandBMC Public Health 11
Maurice, J 2011 Quest for an effective AIDS vaccine takes a new tackThe Lancet 378 213
McGreevey, W 2004
Mills, E. J. 2011 Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from UgandaAnnals of Internal Medicine 155
Murphy, K. MTopel, R. 2003 Measuring the Gains from Medical Research: An Economic ApproachUniversity of Chicago Press
Nordhaus, W. 2003 The health of nations: the contributions of improved health to living standardsMurphy, K. M.Topel, R. H.Measuring the Gains from Medical Research: An Economic ApproachUniversity of Chicago Press
Policy Cures 2010 Neglected Disease Research and Development: Is the Global Financial Crisis Changing R&D?London International Development Centre
Resource Tracking Working Group (for HIV Vaccines and Microbicides) 2011 www.hivresourcetracking.org
Schelling, T. 1968 The life you save may be your ownChase, S. B.Problems in Public Expenditure AnalysisWashington, DC:Brookings Institution
Stover, J. 2007 Resource needs to support orphans and vulnerable children in sub-Saharan AfricaHealth Policy Plan 22 21
Suraratdecha, C.Ainsworth, M.Tangcharoensathien, V.Whittington, D. 2005 The private demand for an AIDS vaccine in ThailandHealth Policy 71 271
UNAIDS 2010 www.unaids.org/en/media/unaids/contentassets/documents/pressstatement/2010/20101123_PS_iprex_en.pdf
UNAIDS 2010 www.unaids.org/globalreport/global_report.htm
UNAIDS 2010
UNAIDS 2011
Usher, D. 1973 An imputation to the measure of economic growth for changes in life expectancyMoss, M.The Measurement of Economic and Social PerformanceNew York:National Bureau of Economic Researchwww.nber.org/chapters/c3616.pdf
Viscusi, W. K.Aldy, J. E. 2003 The value of a statistical life: a critical review of market estimates throughout the worldJournal of Risk and Uncertainty 27 5
Whittington, D.Matsui-Santana, O.Freiberger, J. J.Van Houtven, G.Pattanayak, S. 2002 Private demand for a HIV/AIDS vaccine: evidence from Guadalajara, MexicoVaccine 20 2585